FTC Approves Final Order Requiring Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bristol-Myers Squibb Company’s proposed $74 billion acquisition of Celgene Corporation...